Navigation Links
NUCRYST Approves $0.80 Per Share Cash Distribution to Shareholders
Date:2/12/2009

PRINCETON, NJ, Feb. 12 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp., a developer and manufacturer of medical products that fight infection and inflammation, today announced the results of a special meeting of shareholders. The special meeting of shareholders was called to consider a special resolution ("Special Resolution") pursuant to section 38(1) of the Business Corporations Act (Alberta) to reduce the stated capital of the outstanding NUCRYST common shares by an amount equal to the product of the number of common shares outstanding on the date of the meeting and $0.80 for the purpose of distributing $0.80 cash per share to the common shareholders of NUCRYST.

The distribution which will total $14.7 million equals approximately 59% of NUCRYST's $25.0 million in cash and cash equivalents as of January 31, 2009. NUCRYST set a distribution payable date of February 25, 2009.

The Special Resolution was passed and February 17, 2009 was set as the record date for the distribution. The Toronto Stock Exchange ("TSX") has determined that mandatory special settlement rules will be applied and the common shares will commence trading ex-distribution on the TSX at the opening of the markets on February 17, 2009.

Under NASDAQ OMX rules, the shares will continue to trade with the distribution until its ex-distribution date of February 26, 2009.

NUCRYST also announced the resignation of Thomas E. Gardner from the Board of Directors, effective immediately. Mr. Gardner previously served as Chairman, President, & Chief Executive Officer of NUCRYST until January 2009.

NUCRYST will release its 2008 fourth quarter and full year financial results on Tuesday, February 17, 2009. A conference call will be held that morning to discuss the financial results as well as the impact of the return of capital on NUCRYST's business plans.

All amounts are in U.S. dollars.

About NUCRYST Pharmaceuticals Corp.

NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care coating products to Smith & Nephew plc, which markets these products in over 30 countries under their Acticoat(TM) trademark. NUCRYST has developed its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101, for use in medical devices and as an active pharmaceutical ingredient.

    SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.
    Acticoat(TM) is a trademark of Smith & Nephew plc

This news release contains forward-looking statements within the meaning of securities legislation in the United States and Canada (collectively "forward-looking statements"). With respect to the forward-looking statements contained in this news release, readers are cautioned that numerous risks, uncertainties and other factors could cause our actual results to differ materially from those indicated in these statements including, but not limited to: the effect of the distribution of capital on our liquidity and ability to operate the business; future shareholder actions with respect to our capitalization and strategic direction; the performance of stock markets generally; our ability to satisfy regulatory and stock exchange standards and requirements to maintain our exchange listing; the uncertainty of our future operating results, which are likely to fluctuate; our ability to maintain our collaboration with Smith & Nephew; our reliance on sales of Acticoat(TM) products with our SILCRYST(TM) coatings by Smith & Nephew; the future financial performance and operating performance of Smith & Nephew; and management's response to these factors. Although we have attempted to identify the important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward-looking statements in this release, there may be other factors that cause actual results or events to differ from those expressed or implied in forward looking statements. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our Annual Report on Form 10-K for the year ended December 31, 2007 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, filed with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov and with securities authorities in Canada on SEDAR at www.sedar.com. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and NUCRYST disclaims any intention or obligation to revise or update any forward-looking statements whether as a result of new information, future developments or otherwise after the date hereof.


'/>"/>
SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NUCRYST and Smith & Nephew Revise Agreements
2. Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
3. NUCRYST Pharmaceuticals announces 2007 third quarter results
4. NUCRYST Pharmaceuticals announces year-end results
5. NUCRYST Announces Senior Management Change
6. NUCRYST Announces Management Realignment and R&D Portfolio Change
7. NUCRYST Announces First Quarter 2008 Financial Results
8. NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer
9. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
10. NUCRYST Receives Deficiency Notice from NASDAQ
11. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Viejo, California (PRWEB) , ... January 20, 2017 , ... ... easy to use inside of Final Cut Pro X," said Christina Austin - CEO ... on the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest tale ... each of his children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, ... City, and impassioned writer. , When asked of her new book, Marjorie says, “‘The ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... Positive Expiratory Pressure (OPEP) device, was featured in a study indicating superior performance ... RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated ...
(Date:1/20/2017)... ... , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of ... the creation of published author, Gene Gaapf, a retired truck driver, and a long-time ... been writing since high school and have many different titles,” Gaapf mentions about his ...
(Date:1/19/2017)... ... 20, 2017 , ... Today, the Centers for Medicare & Medicaid Services (CMS) ... Payment Models (APMs) in 2017. Clinicians who participate in APMs are paid for the ... of the Administration’s effort to build a system that delivers better care and one ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Jan. 20, 2017  Palladian Health, a leading ... the launch of an opioid management program which ... opioids and helps stem the growing tide of ... to treat chronic non-cancer pain (back pain, neck ... and lack of evidence regarding long-term effectiveness. ...
(Date:1/20/2017)... 2017 Avillion LLP, a co-developer and financier ... Weinberg , MD MBA as Chief Medical Officer. Dr Weinberg will ... . ... Weinberg has spent more than 17 years as a pharmaceutical and ... micro-cap biotech. Over the course of his career, he has interfaced ...
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Which areas are going to grow at the fastest ... 2026, assessing data, trends, opportunities and prospects. Our ... the most lucrative areas in the industry and the ... forecasted sales across the all the major categories of ...
Breaking Medicine Technology: